For the ecommerce industry, credit card fraud has loomed large as a limiting factor to industry growth for years. According to data from the Federal Reserve, fraud only impacts a fraction of one percent of all purchases made with credit cards, but the catastrophic impact of worst-case scenarios is enough to keep many consumers wary of entering financial information on the web. IFAN Financial, Inc. (OTC: IFAN), through its proprietary iPIN Technologies, is giving consumers a better option, allowing for online payments without the need to expose sensitive personal information.

To better understand the benefits of the iPIN system, consider the effects of the 2014 data breach of nationwide shopping chain Target (NYSE: TGT). Late last year, Target’s databases were accessed by hackers, leaking personal information – including names, addresses, phone numbers and email addresses – of more than 70 million customers around the globe, according to CNN. For shoppers that used traditional online payment channels, this hack would have put their personal information at risk. However, using iPIN Technologies, consumers are able to make online purchases without sharing sensitive personal information, effectively establishing a safer channel for ecommerce payments.

“When you purchase online either using your mobile device or on your PC on the internet [with the iPIN system] and you use your debit card with your PIN, none of your personal information from your card goes to the merchant,” stated Steven Scholl, Chief Financial Officer of IFAN. “They only get the money sent from your bank.”

Moving forward, this technology could be more vital than ever before. In October 2015, banks and credit unions throughout the United States will begin adhering to the new Europay, MasterCard and Visa (EMV) Compliance Mandate. Under this new regulation, participating U.S. merchants will be required to upgrade software and hardware systems to comply with new, chip-based payment cards. While these cards help in-person credit card purchases become more stable and secure, the results in early adopting markets suggest that online security could be a different story.

In Europe, credit and debit card fraud rose by 39 percent over a six year period from 2004 to 2010 following the rollout of EMV-based payment systems, according to Entrepreneur, and a 2014 European Central Bank report indicated that card-not-present payments, including those utilized in ecommerce transactions, were the source of approximately 60 percent of these incidents in 2012. As the United States prepares to make the mandated jump to this new technology, IFAN’s iPIN Technologies could provide the company with a formidable platform to help it realize rapid growth in the years to come.

For more information, visit http://ifanfinancial.com

Let us hear your thoughts: IFAN Financial, Inc. Message Board

If you ask researchers and writers at the MIT Technology Review they will tell you in no uncertain terms that the world wants mobile medical apps (MMAs), and don’t expect demand to slow down during our near or distant future.

At an MIT Technology Review EmTech conference late last year in Boston, Ms. Jeannette Tighe of Sagentia, a global technology advisory and product development company headquartered in Cambridge, U.K., stated that in 2015 at least 500 million smartphone users worldwide will be using health-related apps. Her foresight appears to be right on the money.

By 2017, the market for health related apps is trending to hit $26 billion, according to Research2Guidance, a research and consulting firm that focuses on the global app economy. Driving the market for these apps is in no small part due to the world’s aging population and its subsequent, increasing need for medical care. Tighe also noted that in the US, nearly 20% of its population will be older than 65 by 2030, increasing vulnerability to Alzheimer’s, cardiovascular disease, and a variety of other age-associated conditions.

David Pettigrew, Sagentia’s Vice President of Connected Health, states that, “Benefits to medical-device manufacturers include cost savings through not having to develop a completely new device, leveraging existing platforms while adding more sophisticated sensing and data capabilities, and using an interface that consumers know and understand and is already part of their everyday life.” This confluence of events and technological advances results in the fact that devices are far more likely to be adopted and used correctly.

Consorteum Holdings, Inc.’s (OTC: CSRH) subsidiary, 359, appears to be positioned in the right place at the right time. The subsidiary’s Thin Client Server / Hybrid Mobile Application provides the required security for health care transactions. The health care industry by nature is labor and record intensive, both of which can be expensive. By allowing patients secure access to their medical information, health care institutions can minimize unnecessary expenses.

Possible benefits of Consorteum’s Universal Mobile Interface (UMI) could include optimized patient data processing and reduced costs in areas such as secure account access and mobile health records, medication notifications and automatic refills and real-time insurance co-pay information for prescriptions, just to name a few.

Consorteum markets and licenses the CAPSA software platform in Canada and Mexico. The platform is a mobile content delivery solution that provides digital media to various mobile handsets. Additionally, the platform facilitates transmission of financial information to individual handset owners.

For more information on the company, visit www.consorteum.com

Let us hear your thoughts: Consorteum Holdings, Inc. Message Board

The One World Doll Project, a subsidiary of One World Holdings, Inc. (OWOO), today released an interview with its founder, Trent T. Daniel, in which Daniel discusses the company’s recent national retail distribution deal with Hallmark stores and Wal-Mart Stores, Inc. (NYSE: WMT).

This interview provides shareholders, potential investors and other interested parties the opportunity to understand the details behind the company’s fall 2015 debut in over 2,900 Walmart stores across the nation.

View the video on the company website at http://oneworlddolls.com/investors.

Established in 2010 by Daniel and Stacey McBride-Irby, The One World Doll Project is committed to changing the retail landscape of the doll industry. The Prettie Girls! are a collection of fashion play dolls diverse in culture, interests and style.

For more information, visit www.oneworlddolls.com

Let us hear your thoughts: One World Holdings Message Board

Flexshopper, Inc. (OTCQB: FPAY) is a financial and technology company that provides consumers with a flexible and easy way to get furniture, electronics, appliances and other popular brand name goods with affordable weekly payments. The company’s unique personal shopping assistant platform allows consumers to utilize a patent pending lease-to-own (LTO) payment method to purchase a full selection of qualifying merchandise from some of the country’s most respected retail and e-commerce providers.

By leasing items within Flexshopper’s expansive LTO network, consumers can acquire the products they want without the need for a long-term commitment. Under the company’s model, the merchandise can be returned at any time with proper notice without penalty, or shoppers can continue to pay for one year and take ownership of the leased items.

According to a report by the Association of Progressive Rental Organizations, the LTO industry served approximately 4.8 million customers throughout North America in 2012, accounting for annual revenue of approximately $8.5 billion. This industry performance has provided Flexshopper with a formidable platform to realize strong financial growth in recent years. In the first quarter of 2015, the company recorded lease revenues of more than $3.6 million, marking a year-over-year increase of over $3.5 million.

“We are pleased with our lease originations in the first quarter,” Brad Bernstein, chief executive officer of Flexshopper, stated in a news release. “[W]e are excited to increase our lease originations on all of our channels which include in retail stores, online with our patent pending lease-to-own payment method and on our ecommerce marketplace.”

In March, Flexshopper secured a debt facility of up to $100 million and a $9.35 million equity raise from Middleman Partners, providing the company with the capital needed to promote accelerated growth through its LTO ecommerce marketplace and payment method in the coming months.

“This debt and financing increases our balance sheet strength and ensures that we are well positioned to execute our strategies of… positioning ourselves as the only LTO platform that can provide retailers and e-tailers with multiple digital channels to increase their sales with LTO consumers,” continued Bernstein.

With the persistent expansion of the LTO industry in recent years, Flexshopper is in a strong strategic position to continue improving its financial results in the future. For prospective investors, the company’s newly acquired capital could provide the means for accelerated growth and sustainable returns moving forward.

For more information, visit www.flexshopper.com

Car Monkeys Group, through CarMonkeys.com, is one of the largest and fastest growing online automotive parts distributors in the United States. By offering a complete selection of high quality used parts for a wide range of vehicle makes and models, the company provides its customers with an industry-leading shopping experience.

Using its proprietary part finder, the company makes it simple to find the perfect parts for nearly any vehicle among a network of hundreds of thousands of high quality used parts. Built upon a groundbreaking search and consolidation algorithm, the company’s search function helps consumers navigate issues surrounding part interchangeability to find the perfect part, even if it’s from a completely different vehicle. This allows Car Monkeys to effectively eliminate one of the primary limitations of many of its competitors’ parts networks, strategically positioning the company for continued market growth moving forward.

“The Car Monkeys brand has an established, reputable and expanding presence in the online used car space, and we intend to utilize this success as a platform for continued growth,” Mariusz Girt, chief executive officer of Car Monkeys, stated in a news release.

For consumers, the benefits of utilizing used automotive parts can be massive. According to a report by the Environmental Protection Agency, consumers purchasing used or reconditioned parts can save 50 percent or more, as compared to the cost of new parts. Utilizing recovered automobile parts is also beneficial from an environmental prospective. The North American automotive recycling industry saves an estimated 85 million barrels of oil annually that would otherwise be needed to make new or replacement auto parts.

Since being founded in 2010, Car Monkeys has emerged as a player in the multi-billion dollar automotive recycling industry. By consistently providing its customers with one of the industry’s best warrantees, the company has made significant strides in developing brand confidence and, as a result, opened the door for continued growth.

For prospective investors, Car Monkeys represents a growing brand in one of the country’s most consistently performing industry sectors. Look for the company to continue building on its established presence in the automotive industry moving forward.

Take a closer look at the company, or find that part you need, by visiting www.carmonkeys.com

Let us hear your thoughts: Car Monkeys Group Message Board

According to a report by the American Cancer Society, approximately 25 percent of the estimated 580,000 cancer-related deaths in 2013 were the result of gastrointestinal or digestive cancers. Exact Sciences Corp. (NASDAQ: EXAS), through the continued development and commercialization of Cologuard and related products, is committed to playing a role in substantially reducing this figure moving forward by targeting the complete eradication of colorectal cancer.

Approved by the FDA in August 2014, Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers. In a 10,000-patient clinical study, the company’s revolutionary test effectively diagnosed 92 percent of colon cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Because of this accurate cancer detection ability, Cologuard is currently included in the colorectal cancer screening guidelines of the American Cancer Society.

During the first quarter of 2015, Exact Sciences recorded strong growth for Cologuard, providing the company with a formidable platform for sustained increases in market share moving forward. In the period, 11,000 Cologuard tests were completed and the number of ordering physicians increased from 4,100 at the end of 2014 to 8,300 in the first three months of 2015. The company also expanded its sales team by 75 percent in order to promote continued development of the test’s existing physician network and commercial insurance coverage options.

“We are pleased with the strong launch trajectory of Cologuard,” Kevin Conroy, chairman and chief executive officer of Exact Sciences, stated in a news release. “Demand among patients and physicians and acceptance among commercial insurers is accelerating.”

Since the initial commercialization of Cologuard, Exact Sciences has recorded drastically amplified financial results. In the first quarter of 2015, the company reported total revenues of $4.3 million, a $4 million increase over the same period in 2014. In the coming months, the company will look to build on this development through persistent progress in expanding the test’s utilization rates.

For prospective shareholders, the early market success of Cologuard, as well as the company’s ongoing development of diagnostic tools targeting esophageal, pancreatic and lung cancers, makes Exact Sciences an intriguing investment opportunity moving forward.

For more information, visit www.exactsciences.com

One World Holdings, through its wholly-owned subsidiary, the One World Doll Project, recently announced the next phase of expansion for its acclaimed brand of multicultural fashion and play dolls. The highly anticipated Prettie Girls!™ Tween Scene collection will arrive in approximately 3,000 Walmart stores across the United States in October, providing the company with an opportunity to continue building on the success of its four original Prettie Girls! dolls.

“Our vision in developing the Prettie Girls! Tween Scene collection was to provide young girls with dolls that represent their individual backgrounds, stories, styles, goals and inspirations,” Trent T. Daniel, founder of OWOO, stated in a news release. “It is an honor to launch this new line, which endeavors to reflect America’s children, at Walmart, where America shops.”

The new collection will consist of pre-teen versions of the company’s original dolls, including all four of the Prettie Girls! characters, in addition to the introduction of two new personalities representing additional cultures and backgrounds. In total, the company’s new line will include African-American, Hispanic, South Asian, African, Asian and Caucasian dolls.

The Prettie Girls! were originally launched in 2010 by Daniel and Stacey McBride-Irby, a former designer for toy giant Mattel® who is widely regarded for her role in creating Mattel’s first African-American dolls. Since 2010, OWOO has received orders from a collection of major retailers, including Amazon, Walmart and Toys”R”Us. This increased presence has helped the company post improved financial results in recent months. In April, OWOO announced a 532 percent increase in annual year-over-year revenue in 2014, and the company’s management team expects continued growth moving toward the holiday season.

“It has already been a big year for us and as we continue to expand the Prettie Girls! brand across the nation, we expect to see even more sales performance as the 2015 Christmas season draws closer,” stated Joanne Melton, chief executive officer of OWOO.

According to the Toy Association, the domestic toy industry accounted for over $18 billion in revenue in 2014, with $2.32 billion attributed to the doll category. Through the release of the Prettie Girls! Tween Scene collection later this year, OWOO will be in a strong position to continue expanding upon its current share of the thriving market. For prospective investors, this announcement could foreshadow an extremely promising holiday season later this year.

For more information, visit www.oneworlddolls.com

Let us hear your thoughts: One World Holdings Message Board

Transgenomic, Inc. (NASDAQ: TBIO) is a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through progressive diagnostic technologies, such as its revolutionary ICE-COLD PCR™ (MX-ICP). Through this technology, the company provides more sensitive and accurate mutation detection without major costs or impact to current processes.

In May, Transgenomic built on the versatility of its MX-ICP platform through the launch of a novel epidermal growth factor receptor (EGFR) CLIA test for mutation detection in cancer patients, effectively opening the door for more informed diagnoses, better treatment decisions and ongoing patient monitoring moving forward. The first tests using this platform were for the detection of EGFR T790M mutations, which have been linked to patient resistance of current non-small cell lung cancer (NSCLC) treatment options.

“Launching our multiplexed ICE COLD-PCR-based CLIA mutation detection service for oncologists and their patients is a major milestone for Transgenomic and, we believe, an important advance for the field of precision medicine,” Paul Kinnon, president and chief executive officer of Transgenomic, stated in a news release. “The unsurpassed accuracy of MX-ICP and its ability to produce highly sensitive and accurate results from small amounts of almost any type of patient sample, especially liquid biopsies, allows broad use.”

MX-ICP has been shown effective in the detection of mutation with a range of biofluid samples – including blood, plasma, serum, urine, sputum and bronchial lavage – allowing for highly accurate, non-invasive diagnostics of all known and unknown mutations.

In recent months, Transgenomic has leveraged the considerable market for its diagnostic technologies and clinical and research services to record improved financial results. During the first quarter of 2015, the company’s net sales were recorded at a 4 percent year-over-year increase, with laboratory services sales increasing by over 30 percent for the same period.

“The company made good progress in the first quarter in strengthening our historical businesses while preparing for the imminent launch of our breakthrough technology: Multiplexed ICE-COLD PCR™,” continued Kinnon. “We achieved a double digit percentage increase in overall net sales excluding the divested Surveyor product line, including a robust 32 percent increase in the critical laboratory services segment.”

Moving forward, look for Transgenomic to continue building on its recent progress in order to maximize industry growth. For prospective investors, continued industry adoption of the company’s MX-ICP technology could provide ample opportunity to realize sustainable returns in the years to come.

For more information, visit www.transgenomic.com

Inergetics develops patented nutritional supplement products under a consortium of brands that serve the clinical nutrition, long-term care (senior care) and sports nutrition markets. Through its diverse line of products, Inergetics participates in a more than $104 billion global market with multi-billion dollar industry leaders like HerbaLife Ltd. (NYSE:HLF) and GNC Holdings, Inc. (NYSE:GNC).

Comprised of high-quality ingredients and proprietary formulations, Inergetics’ products are designed to improve overall health, physical recovery, athletic performance and quality of life for patients and consumers. Inergetics’ brand portfolio includes:

• Martha Stewart™ Essentials – a complete line of whole food-based supplements created specifically for women, developed under a partnership between Martha Stewart Essentials and Inergetics.
• Surgex Sports Nutrition’s – SURGEX® is a clinically proven, performance-enhancing formula designed to help athletes build lean muscle, increase energy and peak power, improve endurance, and quicken recovery time.
• Bikini Ready Lifestyle – an innovative natural ingredients formula built on nutraceutical science to help maintain weight; used by professional surfers Anastasia Ashley and Christa Alves.
• SlimTrim™ – a premium value diet supplement designed to support a healthy lifestyle and diet for weight loss. The SlimTrim formula features acai, resveratrol, green tea and other leading diet ingredients.
• OmEssentials® – line of scientifically advanced nutritional supplements designed to improve health and wellness of yoga practitioners and active individuals.
• Nulief™ CBD – cannabidiol (CBD)-based nutritional supplements.

Though Inergetics various products are similar to both HerbaLife and GNC in terms of product context, the companies’ sales strategy greatly differs. HerbaLife sells its products through independent distributors, while GNC products are sold online or one of the company’s numerous brick-and-mortar locations.

Inergetics brands are available both domestically and internationally at thousands of premier locations, including Bed Bath & Beyond (BBBY), PriceSmart (PSMT), Walgreens (WAG), Whole Foods (WFM), and a range of private retailers, as well as leading e-tailers such as Amazon (AMZN), Bodybuilding.com, CVS.com, Drugstore.com and more.

Inergetics, HerbaLife and GNC all participate in the growing global nutrition and supplements market breaks, which breaks into a variety of predominant and rapidly expanding categories. According to Persistence Market Research analysis, the global sports nutrition market alone, just one of the subcategories in which Inergetics participates, will achieve CAGR of 9% between 2013 and 2019, reaching $37.7 billion by the end of the seven-year spread.

Inergetics continues to expand its distribution network as it seeks deeper penetration in the global nutrition and supplements market, taking advantage of its diverse product line. In an earlier news release, the company noted its increasing strength, particularly in the Midwest, gaining momentum from growing demand in the health and wellness category.

For more information, visit www.inergetics.com

Let us hear your thoughts below:

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company’s lead immunotherapy candidate, bavituximab, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of second-line non-small lung cancer and is currently in phase III development for this indication. Bavituximab is also being evaluated for several solid tumor indications, including non-small cell lung cancer, rectal cancer and advanced melanoma.

“These new trials represent large market opportunities for the bavituximab clinical program that can add significant value,” Steven King, president and chief executive officer of Peregrine, stated in a news release. “[W]e believe we are setting the stage for many significant value driving events through 2015 and into 2016.”

Through its wholly-owned subsidiary, Avid Bioservices, Peregrine differentiates itself from competitors by offering in-house cGMP manufacturing capabilities, allowing the company to provide development and biomanufacturing services to support the needs of its clinical trials, as well as those of outside customers. In December, the company announced a substantial expansion to Avid’s current manufacturing capacity through the construction of a state-of-the-art 40,000 square foot biotechnology facility located adjacent to the company’s current campus. With this new facility, which is anticipated to be ready for cGMP production of biotechnology products next month, the company will be better equipped to meet the growing needs of Avid’s existing and future clients, as well as the expected commercialization of bavituximab.

“We are very pleased with the rapid progress by which this expansion is advancing as this is a key component to further demonstrating Avid as a leading provider of high quality biotechnology contract manufacturing services,” continued King. “The design and the features that we have employed in this expansion will truly be an integral part to the future growth of this unique part of our business.”

Moving forward, Peregrine will look to complete enrollment of its 600 patient phase III clinical trial of bavituximab, which is designed to evaluate the safety, tolerability and efficacy of the candidate as a second-line treatment in patients with non-squamous, non-small cell lung cancer. Look for the company to continue making strides toward the planned commercialization of bavituximab in the years to come, providing significant opportunity for sustainable shareholder returns along the way.

For more information, visit www.peregrineinc.com